Skip to main content
. Author manuscript; available in PMC: 2020 Dec 1.
Published in final edited form as: J Subst Abuse Treat. 2019 Aug 16;107:29–37. doi: 10.1016/j.jsat.2019.08.009

Table 3.

Cognitive Measures

Galantamine Placebo Total Statistics: 3 Group (8, 16mg, placebo)
Task Variable (Cognitive Domain) Timepoint 8 mg 16 mg Time Group Groupx Time
mean sd n mean sd n mean sd n mean sd n F, p F, p F, p
A. Primary Cognitive Outcomes
RVP A’ (Attention/Signal Detection) Baseline (Wk 0) 0.86 0.06 17 0.86 0.05 12 0.85 0.08 15 0.86 0.06 44 .41, .53 .38, .69 1.31, .28
End of Treatment (Wk 12) 0.88 0.07 17 0.84 0.12 12 0.87 0.08 15 0.87 0.09 44
Longest Digit Span Forward (Memory Capacity) Baseline (Wk 0) 5.9 1.7 22 5.7 1.3 13 6.4 2.3 17 6 1.8 52 17.18, .00 1.43, .25 .48, .62
End of Treatment (Wk 12) 6.5 1.4 22 6.8 1 13 7.4 1.2 17 6.9 1.3 52
Longest Digit Span Backwards (Working Memory) Baseline (Wk 0) 4.2 1.7 22 3.2 0.9 13 4 1.7 17 3.9 1.6 52 4.9, .03 .58, .56 5.89, .005
End of Treatment (Wk 12) 4.2 1.2 22 4.3 1.4 13 3.9 1.6 17 4.1 1.4 52
Stop Signal Response Time (SSRT) (Response Inhibition) Baseline (Wk 0) 215.3 89.9 17 277.2 142.6 12 244.1 111.4 15 242 113.5 44 .01, .92 .67, .52 .22, .81
End of Treatment (Wk 12) 241.9 140.2 17 267.9 196.6 12 234.8 129.2 15 246.6 151.1 44
Drug Stroop Effect (Attentional Bias) Baseline (Wk 0) −2.25 13.5 16 3.1 5.5 3 1.5 4.3 15 0.6 9.1 44 .13, .72 .42, .66 2.11, .13
End of Treatment (Wk 12) 2.3 6.4 16 0.22 2.9 13 1.4 3.9 15 1.4 4.8 44
B. Secondary Cognitive Outcomes
Digit Span: Forward Total Score (Memory Capacity) Baseline (Wk 0) 9.6 3 22 9.9 2.3 13 10.7 2.1 19 10.1 2.6 54 6.23, .02 .78, .47 .27, .77
End of Treatment (Wk 12) 10.5 2.6 22 10.7 1.8 13 11.2 3.1 19 10.8 2.6 54
Digit Span: Backwards Total Score (Working Memory) Baseline (Wk 0) 8.3 3.1 22 7.2 1.5 13 7.6 1.9 19 7.8 2.4 54 .79, .38 .82, .44 2.03, .14
End of Treatment (Wk 12) 8.3 2.1 22 8.5 2.7 13 7.3 2.7 19 8 2.5 54
RVP: B” (Response Bias) Baseline (Wk 0) 0.77 0.42 17 0.91 0.13 12 0.77 0.22 15 0.81 0.3 44 2.13, .15 .20, .82 4.44, .02
End of Treatment (Wk 12) 0.81 0.16 17 0.57 0.56 12 0.81 0.19 15 0.74 0.34 44
RVP: False Alarm (Motor Impulsivity) Baseline (Wk 0) 0.04 0.08 17 0.01 0.02 12 0.03 0.04 15 0.03 0.05 44 .03, .87 .18, .84 1.93, .16
End of Treatment (Wk 12) 0.03 0.03 17 0.03 0.04 12 0.02 0.02 15 0.03 0.03 44
SST: Median Correct Go RT (Response Speed) Baseline (Wk 0) 706.3 260 17 619.7 285.7 12 680 158.3 15 673.7 235.4 44 .87, .36 .02, .99 1.51, .23
End of Treatment (Wk 12) 608.6 201.6 17 669.7 323.5 12 631.5 150.6 15 633.1 223.3 44
SST: SD Correct Go RT (Attention) Baseline (Wk 0) 276.5 138.5 17 302.3 174.6 12 363.4 214.4 15 313.1 177 44 3.36, .07 1.05, .36 .15, .86
End of Treatment (Wk 12) 337.8 262.9 17 410.6 276.1 12 492.6 530.5 15 410.4 375.9 44
Drug Stroop: Mean RT for Correct Neutral Trials Baseline (Wk 0) 791.8 189.4 16 808.2 112.7 13 854.5 142.2 15 818 153 44 4.64, .04 .78, .47 .52, .60
End of Treatment (Wk 12) 772.0 186 16 750 138.2 13 828.7 180.1 15 784.8 170.5 44
Drug Stroop: Mean RT for Correct Drug Trials Baseline (Wk 0) 789.5 191 16 811.2 112.6 13 856 140.8 15 818.6 153.4 44 4.48, .04 .79, .46 .71, .50
End of Treatment (Wk 12) 774.3 184.8 16 750.3 139.1 13 830.1 179.9 15 786.2 170.2 44

Abbreviations: RVP= Rapid Visual Information Processing Task; SST= Stop Signal Task; RT= Response Time; Wk= Week Bold indicates statistical significance (p<0.05); bold italics indicate a trend significance (p<0.10).